Literature DB >> 11901754

The cellular and molecular mechanism of CD4/CD8 lineage commitment.

Koji Yasutomo1.   

Abstract

A unique feature of alpha beta T-cell development is the central role played by clonally distributed T-cell receptors (TCR), which are encoded by somatically rearranged gene segments that produce a diverse, non-germline encoded set of receptors. Fate determination in individual T-cells is mediated by ligand-receptor signals that arise from unprogrammed genetic interactions, under conditions in which the relevant ligand concentration and the receptor affinity are not evolutionarily controlled. A precursor T-cell with a TCR that either fails to demonstrate appreciable self-reactivity or binds with high affinity to reasonably abundant self-peptide major histocompatibility complex (MHC)-ligands will undergo apoptosis. In contrast, a precursor T-cell that shows lower affinity to moderately abundant ligands will receive suitable signals for survival and maturation. Recently, we have developed a rapid in vitro two-step organ culture system that permits homogeneous populations of non-transformed precursor T-cells to undergo selective commitment to the CD4 or CD8 lineage. Using this model, we have shown that the choice of positively selected ab T-cells between the CD4 helper and CD8 cytotoxic lineages is regulated by the TCR signaling duration in response to self-peptides bound to the MHC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901754

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  2 in total

1.  Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report.

Authors:  Ziwei Guo; Chao Meng; Xing Wei; Chuanhao Tang; Jun Liang
Journal:  Thorac Cancer       Date:  2018-03-02       Impact factor: 3.500

2.  PARG regulates the proliferation and differentiation of DCs and T cells via PARP/NF‑κB in tumour metastases of colon carcinoma.

Authors:  Jie-Qiong Wang; Yi Tang; Qing-Shu Li; Ming Xiao; Ming Li; Yong-Tao Sheng; Yi Yang; Ya-Lan Wang
Journal:  Oncol Rep       Date:  2019-03-07       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.